bioAffinity Technologies, Inc. has officially filed a registration statement with the U.S. Securities and Exchange Commission (SEC) to offer shares of its common stock. This move, filed on November 20, 2026, is a pivotal step for the company as it seeks to raise capital to support its growth initiatives.

The filing comes at a time when the commercial physical and biological research industry is witnessing a surge in companies looking to attract public investment. As bioAffinity Technologies positions itself for potential expansion, it may influence other players in the industry to consider similar funding strategies.

Background

bioAffinity Technologies, Inc. is a Delaware-based company operating in the commercial physical and biological research sector, classified under the Standard Industrial Classification (SIC) code 8731. The company trades on the Nasdaq under the ticker symbols BIAF and BIAFW. The firm focuses on developing innovative solutions in the field of biological research, aiming to improve health outcomes through its technologies.

What the Filing Says

The registration statement indicates that bioAffinity Technologies plans to offer 999,673 shares of its common stock. This includes 980,072 shares that are issuable upon exercise of Series C warrants and 19,601 shares from placement agent warrants. The company clarified that it is not selling any shares under this prospectus and will not receive proceeds from the sale of shares by the selling stockholders, although it will benefit from any warrants exercised for cash.

Impact

This registration statement may have significant implications for various stakeholders. Current shareholders may see this as an opportunity for increased liquidity, while potential investors might view it as a chance to participate in the company's growth journey. Additionally, the filing could prompt competitors in the commercial physical and biological research sector to reassess their own funding strategies and public offerings.

What's Next

The filing does not specify what happens next, but typically, the next steps may involve waiting for the SEC to declare the registration statement effective, allowing the company to proceed with the offering.

For more details, the filing can be accessed through the SEC's website under accession number 0001493152-26-053519.